BusinessAxsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business UpdateBy Nasdaq OMXMay 8, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 7, 2018, 12:01 PM UTC
BusinessAxsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and DextromethorphanBy Nasdaq OMXFeb 26, 2018, 12:00 PM UTC
